In The News

In The News

MD+DI | March 21, 2018
Quanterix teams up with DestiNA to develop assays to detect liver toxicity in patients.
Bloomberg | February 05, 2018
Bloomberg reporter Anne Mostue interviews Kevin Hrusovsky in segment called, "The Race to Diagnose CTE in the Living"
Quartz | February 03, 2018
"What we need is collaboration among scientists, researchers, the NFL and other contact sports governing bodies to develop a blood test that can be used to monitor players’ brain health, as a blood test is a better alternative to CT scans and subjective tests that are entrenched in current protocol…
SelectScience Interview | January 29, 2018
Ralph McDade explains the importance of using ultra-sensitive immunoassays from Quanterix
SelectScience Interview | January 31, 2018
Ultrasensitive Simoa technology to advance research into tumor-derived exosomes at the University of Pittsburgh Cancer Institute, led by Theresa Whiteside, professor of pathology
SelectScience Interview | January 29, 2018
Henrik Zetterberg discusses the use of ultrasensitive biomarker assays from Quanterix for Alzheimer’s research
SelectScience Interview | January 29, 2018
Bonnie Howell, Executive Director at Merck, discusses the use of ultrasensitive Quanterix technology to develop novel therapies for HIV and shares her hopes for a future world, free of the disease
TheStreet | January 22, 2018
With a boost from the NFL and its own IPO, Quanterix hopes to engage biopharma companies to use its platform to speed safety and efficacy results for neurology, oncology and inflammation pipelines.
GenomeWeb | January 17, 2018
Fresh off a $74 million initial public offering, Quanterix is looking to make immediate inroads in the biotech and pharma research space with longer-term plans to move into diagnostics and health monitoring.
Medical Device and Diagnostic Industry | January 16, 2018
Would you rather get a biopsy or a blood test to check for prostate cancer?